S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:EDIT

Editas Medicine - EDIT Stock Forecast, Price & News

$17.99
-1.14 (-5.96%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.15
$18.76
50-Day Range
$10.00
$19.42
52-Week Range
$9.59
$73.03
Volume
1.98 million shs
Average Volume
1.80 million shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.10

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
55.0% Upside
$27.89 Price Target
Short Interest
Bearish
23.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.91
Upright™ Environmental Score
News Sentiment
0.25mentions of Editas Medicine in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$86,233 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.37) to ($3.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

548th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

84th out of 174 stocks

EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Trading Down 6.6 %

Shares of NASDAQ:EDIT traded down $1.27 during midday trading on Tuesday, reaching $17.86. 15,165 shares of the company's stock traded hands, compared to its average volume of 1,741,213. The company has a fifty day simple moving average of $14.03 and a two-hundred day simple moving average of $15.26. Editas Medicine has a 1 year low of $9.59 and a 1 year high of $73.03.

Editas Medicine (NASDAQ:EDIT - Get Rating) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06. Editas Medicine had a negative net margin of 580.16% and a negative return on equity of 34.83%. The business had revenue of $6.36 million for the quarter, compared to analyst estimates of $4.29 million. During the same quarter last year, the business earned ($0.81) earnings per share. The company's revenue for the quarter was up 1578.6% compared to the same quarter last year. On average, equities research analysts forecast that Editas Medicine will post -3.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Morgan Stanley upped their target price on Editas Medicine from $16.00 to $17.00 and gave the company an "underweight" rating in a research report on Tuesday, April 12th. Oppenheimer reduced their target price on shares of Editas Medicine from $55.00 to $28.00 in a report on Thursday, May 5th. Robert W. Baird lowered their price target on shares of Editas Medicine from $44.00 to $33.00 in a report on Monday, April 18th. The Goldman Sachs Group cut their price target on Editas Medicine from $10.00 to $8.00 and set a "sell" rating on the stock in a research report on Tuesday, May 24th. Finally, Barclays upped their target price on Editas Medicine from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 4th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $33.10.

Insiders Place Their Bets

In other news, EVP Mark S. Shearman sold 5,145 shares of Editas Medicine stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $10.06, for a total value of $51,758.70. Following the sale, the executive vice president now directly owns 68,349 shares of the company's stock, valued at $687,590.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 7,795 shares of company stock worth $82,340. Corporate insiders own 0.44% of the company's stock.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

Editas Medicine (NASDAQ:EDIT) PT Raised to $17.00 at Barclays
Editas Medicine: Q2 Earnings Insights
Editas Medicine (NASDAQ:EDIT) Trading 9.8% Higher
Editas Medicine (NASDAQ:EDIT) Shares Up 3.8%
Editas Medicine Tops Q1 EPS by 5c
Editas Medicine Q1 2022 Earnings Preview
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
8/03/2022
Today
8/09/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.89
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+84.0%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
9 Analysts

Profitability

Net Income
$-192,500,000.00
Net Margins
-580.16%
Pretax Margin
-580.16%

Debt

Sales & Book Value

Annual Sales
$25.54 million
Book Value
$8.09 per share

Miscellaneous

Free Float
68,435,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
2.03

Key Executives














EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2022?

9 Wall Street research analysts have issued twelve-month target prices for Editas Medicine's stock. Their EDIT share price forecasts range from $8.00 to $60.00. On average, they expect the company's share price to reach $27.89 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How has Editas Medicine's stock price performed in 2022?

Editas Medicine's stock was trading at $26.55 at the start of the year. Since then, EDIT stock has decreased by 34.5% and is now trading at $17.40.
View the best growth stocks for 2022 here
.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) released its quarterly earnings results on Wednesday, August, 3rd. The company reported ($0.78) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.06. The firm earned $6.36 million during the quarter, compared to analysts' expectations of $4.29 million. Editas Medicine had a negative net margin of 580.16% and a negative trailing twelve-month return on equity of 34.83%. Editas Medicine's revenue was up 1578.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.81) EPS.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.09%), Nikko Asset Management Americas Inc. (1.09%), Green Alpha Advisors LLC (0.50%), Mirae Asset Global Investments Co. Ltd. (0.45%), ARK Investment Management LLC (0.37%) and Connor Clark & Lunn Investment Management Ltd. (0.34%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $17.40.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $1.20 billion and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.